This presentation will draw on the experiences of people receiving and providing Opioid Agonist Treatment (OAT) during COVID-19.

The COVID-19 pandemic required Opioid Agonist Treatment (OAT) services to adapt quickly to ensure continuity of care. The CHOICE Study uses data collected from 70 in-depth interviews (40 people receiving OAT; 30 providers) to explore how OAT services in Australia responded to COVID-19 and the wider implications of the pandemic for people receiving OAT. Study findings will inform clinical practice and health policy, and highlight areas of future research for people who are dependent on opioids.

About the speaker

Anna Conway obtained her Master of Public Health at the Universitat Pompeu Fabra, Barcelona and has since worked as a research assistant on projects related to HIV and hepatitis C testing. Anna is currently in the second year of her PhD at the Kirby Institute and Centre for Social Research in Health. Her doctoral research investigates health service use by people dependent on opioids.